Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 12/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27207460 | 0.85 | STING1 (0.41) | STING1ADORA2A | |
| SCHEMBL27204002 | 0.85 | STING1 (0.41) | STING1ADORA2A | |
| SCHEMBL28421225 | 0.83 | STING1 (0.48) | STING1CYP3A4BRD4CYP2D6CYP2C9 | |
| SCHEMBL19451470 | 0.83 | STING1 (0.48) | STING1CYP3A4BRD4CYP2D6CYP2C9 | |
| SCHEMBL29405998 | 0.83 | STING1 (0.48) | STING1CYP3A4BRD4CYP2D6CYP2C9 | |
| SCHEMBL21620360 | 0.83 | STING1 (0.42) | STING1ADORA2A | |
| SCHEMBL21620380 | 0.83 | DRD3 (0.39) | STING1ADORA2A | |
| SCHEMBL21643887 | 0.83 | STING1 (0.54) | STING1CYP3A4BRD4CYP2D6CYP2C9 | |
| SCHEMBL21616424 | 0.82 | STING1 (0.41) | STING1ADORA2A | |
| Bromide SCHEMBL21616426 | 0.82 | STING1 (0.41) | STING1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132493-A1 | IMIDAZOPYRIDINE DERIVATIVES AS STING AGONISTS | FULGENT GENETICS INC (US) | 2024-04-25 | — | — | US | disclosed |
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-30 | — | — | US | disclosed |
| WO-2020010451-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020010451-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | TRILLIUM THERAPEUTICS INC. (CA) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031825-A1 | HETEROAROMATIC-FUSED IMIDAZOLYL AMIDES, COMPOSITIONS AND USES THEREOF AS STING AGONISTS | STING1, MAVS, IRF3 | STING1 1/4885CYP3A4 4386/4885CSNK1D 1040/4885 |
| US-20240132493-A1 | IMIDAZOPYRIDINE DERIVATIVES AS STING AGONISTS | STING1, IRF3, MAVS | STING1 1/4885CYP3A4 3589/4885CSNK1D 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.